HansBiomed Statistics

Total Valuation

HansBiomed has a market cap or net worth of KRW 113.77 billion. The enterprise value is 143.18 billion.

Market Cap	113.77B
Enterprise Value	143.18B

Important Dates

The next estimated earnings date is Wednesday, February 12, 2025.

Earnings Date	Feb 12, 2025
Ex-Dividend Date	n/a

Share Statistics

HansBiomed has 12.99 million shares outstanding. The number of shares has increased by 20.83% in one year.

Current Share Class	n/a
Shares Outstanding	12.99M
Shares Change (YoY)	+20.83%
Shares Change (QoQ)	-0.28%
Owned by Insiders (%)	26.25%
Owned by Institutions (%)	0.77%
Float	7.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.40
PB Ratio	1.70
P/TBV Ratio	1.72
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 67.60, with an EV/FCF ratio of -171.33.

EV / Earnings	-19.82
EV / Sales	1.76
EV / EBITDA	67.60
EV / EBIT	n/a
EV / FCF	-171.33

Financial Position

The company has a current ratio of 0.99, with a Debt / Equity ratio of 0.54.

Current Ratio	0.99
Quick Ratio	0.38
Debt / Equity	0.54
Debt / EBITDA	6.06
Debt / FCF	-43.59
Interest Coverage	0.35

Financial Efficiency

Return on equity (ROE) is -13.32% and return on invested capital (ROIC) is 0.40%.

Return on Equity (ROE)	-13.32%
Return on Assets (ROA)	0.32%
Return on Capital (ROIC)	0.40%
Revenue Per Employee	638.88M
Profits Per Employee	-56.87M
Employee Count	127
Asset Turnover	0.66
Inventory Turnover	1.05

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.81% in the last 52 weeks. The beta is 0.69, so HansBiomed's price volatility has been lower than the market average.

Beta (5Y)	0.69
52-Week Price Change	-29.81%
50-Day Moving Average	8,243.00
200-Day Moving Average	10,590.25
Relative Strength Index (RSI)	50.81
Average Volume (20 Days)	12,200

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HansBiomed had revenue of KRW 81.14 billion and -7.22 billion in losses. Loss per share was -558.00.

Revenue	81.14B
Gross Profit	51.75B
Operating Income	625.60M
Pretax Income	-6.63B
Net Income	-7.22B
EBITDA	6.01B
EBIT	625.60M
Loss Per Share	-558.00

Full Income Statement

Balance Sheet

The company has 7.26 billion in cash and 36.43 billion in debt, giving a net cash position of -29.17 billion or -2,246.15 per share.

Cash & Cash Equivalents	7.26B
Total Debt	36.43B
Net Cash	-29.17B
Net Cash Per Share	-2,246.15
Equity (Book Value)	67.12B
Book Value Per Share	5,149.32
Working Capital	-385.31M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.76 billion and capital expenditures -2.59 billion, giving a free cash flow of -835.74 million.

Operating Cash Flow	1.76B
Capital Expenditures	-2.59B
Free Cash Flow	-835.74M
FCF Per Share	-64.35

Full Cash Flow Statement

Margins

Gross margin is 63.78%, with operating and profit margins of 0.77% and -8.90%.

Gross Margin	63.78%
Operating Margin	0.77%
Pretax Margin	-8.17%
Profit Margin	-8.90%
EBITDA Margin	7.41%
EBIT Margin	0.77%
FCF Margin	n/a

Dividends & Yields

HansBiomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.83%
Shareholder Yield	-20.83%
Earnings Yield	-6.37%
FCF Yield	-0.73%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HansBiomed has an Altman Z-Score of 2.35. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.35
Piotroski F-Score	n/a